Your browser doesn't support javascript.
loading
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes.
Sengupta, Satyaki; Das, Sanjukta; Crespo, Angela C; Cornel, Annelisa M; Patel, Anand G; Mahadevan, Navin R; Campisi, Marco; Ali, Alaa K; Sharma, Bandana; Rowe, Jared H; Huang, Hao; Debruyne, David N; Cerda, Esther D; Krajewska, Malgorzata; Dries, Ruben; Chen, Minyue; Zhang, Shupei; Soriano, Luigi; Cohen, Malkiel A; Versteeg, Rogier; Jaenisch, Rudolf; Spranger, Stefani; Romee, Rizwan; Miller, Brian C; Barbie, David A; Nierkens, Stefan; Dyer, Michael A; Lieberman, Judy; George, Rani E.
Affiliation
  • Sengupta S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Das S; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Crespo AC; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Cornel AM; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Patel AG; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Mahadevan NR; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
  • Campisi M; Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Ali AK; Princess Máxima Center for Pediatric Oncology, Utrecht University, Utrecht, The Netherlands.
  • Sharma B; Department of Developmental Neurobiology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Rowe JH; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Huang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Debruyne DN; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Cerda ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Krajewska M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Dries R; Cellular Therapy and Stem Cell Transplant Program, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Chen M; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Zhang S; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Soriano L; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Cohen MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Versteeg R; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Jaenisch R; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Spranger S; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Romee R; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Miller BC; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Barbie DA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Nierkens S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Dyer MA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Lieberman J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • George RE; Whitehead Institute for Biomedical Research, Cambridge, MA, USA.
Nat Cancer ; 3(10): 1228-1246, 2022 10.
Article in En | MEDLINE | ID: mdl-36138189
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adrenergic Agents / Neuroblastoma Limits: Humans Language: En Journal: Nat Cancer Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adrenergic Agents / Neuroblastoma Limits: Humans Language: En Journal: Nat Cancer Year: 2022 Document type: Article